LAVAL, Quebec — Valeant Pharmaceuticals on Monday announced that certain of its subsidiaries have entered into settlement agreements with Actavis related to Actavis' generic versions of Tiazac XC.
Valeant's subsidiaries, Valeant Canada and Valeant International Bermuda, and Actavis Pharma Company have entered into an agreement to settle outstanding patent litigation related to Actavis' generic version of Tiazac XC (diltiazem hydrochloride) 180 mg, 240 mg, 300 mg and 360 mg capsules. Tiazac XC is a calcium cellular influx inhibitor (slow channel blocker) indicated for treatment of hypertension. It is marketed in Canada by Valeant Canada.
Under the terms of the agreement, which is pending approval from the Federal Court of Canada, it will result in a stay of this application until certain events occur and a dismissal of all remaining proceedings and appeals.
Separately, Valeant also granted Actavis license to market generic Acanya gel beginning July 1, 2018.